Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias
Early Alterations of Peripheral Mitochondrial Function and Metabolomic Profile in Patients With Alzheimer's Disease and Related Dementias
Centre Hospitalier Universitaire de Nice
170 participants
Jul 1, 2025
INTERVENTIONAL
Conditions
Summary
This project aims to study on one hand the early mitochondrial alterations, common or specific, occurring in peripheral cells of patients with Alzheimer's disease or related dementia and, on the other hand, identify the metabolomic biomarkers that may be at the origin of mitochondrial disturbances associated with the disease. This will be the first study combining functional analyses of mitochondria and exploratory metabolomic assessments in the same cohort at early stages of the disease.
Eligibility
Inclusion Criteria7
- Neurocognitive disorder with spontaneous complaint or reported for at least 6 months
- Diagnostic process according to current Haute Autorité de Santé (HAS) recommendations.
- cerebrospinal fluid biomarker dosage done within the study center and agreement to bio-collection of residual cerebrospinal fluid
- Patient having agreed to sign the informed consent
- Patient affiliated or beneficiary of a social security scheme
- For alzheimer group : diagnosis of Alzheimer's disease according to NIA-AA 2024 criteria (presence of a pathogenic amyloid process in the cerebrospinal fluid)
- For non alzheimer group : diagnosis of mild or major neurocognitive disorder according to Manuel diagnostique et statistique des troubles mentaux edition 5 (DSM-V) criteria, not linked to Alzheimer's disease (absence of pathogenic amyloid process in the cerebrospinal fluid)
Exclusion Criteria1
- \- Vulnerable people
Interventions
Each patient will be evaluated by Mini-Mental State Examination (MMSE) and will have a blood draw
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06880406